Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more
Amplia Therapeutics Limited (INNMF) - Total Liabilities
Latest total liabilities as of September 2025: $1.61 Million USD
Based on the latest financial reports, Amplia Therapeutics Limited (INNMF) has total liabilities worth $1.61 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amplia Therapeutics Limited - Total Liabilities Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amplia Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Amplia Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
India | ₹3.70 Billion |
|
TGAAF
PINK:TGAAF
|
USA | $5.11 Million |
|
Target Global Acquisition I Corp
PINK:TGAA
|
USA | $5.11 Million |
|
Hank Payments Corp.
PINK:HNKPF
|
USA | $13.17 Million |
|
KIOCL Limited
NSE:KIOCL
|
India | ₹5.49 Billion |
|
Titania Holding AB Series B
ST:TITA-B
|
Sweden | Skr3.70 Billion |
|
HEALTH NET
F:HNT
|
Germany | €1.45 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Amplia Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amplia Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amplia Therapeutics Limited (2010–2025)
The table below shows the annual total liabilities of Amplia Therapeutics Limited from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $1.91 Million | -44.20% |
| 2024-03-31 | $3.43 Million | +20.29% |
| 2023-03-31 | $2.85 Million | +8.07% |
| 2022-03-31 | $2.64 Million | +388.95% |
| 2021-03-31 | $539.13K | +5.58% |
| 2020-03-31 | $510.62K | -3.08% |
| 2019-03-31 | $526.86K | +88.55% |
| 2018-03-31 | $279.42K | -69.22% |
| 2017-03-31 | $907.87K | -11.97% |
| 2016-03-31 | $1.03 Million | +127.72% |
| 2015-03-31 | $452.90K | +12.18% |
| 2014-03-31 | $403.73K | +111.38% |
| 2013-03-31 | $191.00K | -92.51% |
| 2012-03-31 | $2.55 Million | +43.32% |
| 2011-03-31 | $1.78 Million | -20.18% |
| 2010-03-31 | $2.23 Million | -- |